Rodman & Renshaw initiated coverage on PolyPid Ltd. (NASDAQ:PYPD), a late-stage biopharmaceutical company, with a Buy rating and a price target of $13.00. PolyPid specializes in the controlled and ...
Evercore ISI analyst Michael Binetti has maintained their bullish stance on LULU stock, giving a Buy rating yesterday.Invest with Confidence: ...
Kimberly-Clark forecast annual adjusted profit growth ahead of Wall Street estimates and reported better-than-expected ...
General Motors Co.'s full year net income was down 41% from 2023 after losing $3 billion in the fourth quarter.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback